Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.65 |
| ▸ | THRB | P10828 | 5/20 | 0.65 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.64 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.61 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802422 | 0.86 | PTGDR2 (0.76) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL5248719 | 0.85 | PTGDR2 (0.54) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL4210031 | 0.85 | THRA (0.60) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL7963412 | 0.85 | PLA2G2A (0.65) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL2004289 | 0.83 | PLA2G2A (0.59) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL4209387 | 0.82 | PTGDR2 (0.74) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL9584026 | 0.82 | FOLH1 (0.50) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL1939892 | 0.81 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL4211522 | 0.81 | PTGDR2 (0.72) | THRATHRBPTGDR2PLA2G2APLA2G1B | |
| SCHEMBL13802405 | 0.81 | PTGDR2 (0.70) | THRATHRBPTGDR2PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | THRA 3787/4885THRB 3290/4885PTGDR2 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.